acute myeloid leukemia (AML) | Page 4 | Aplastic Anemia & MDS International Foundation Return to top.

acute myeloid leukemia (AML)

2022 Seattle, WA, Patient and Family Virtual Conference

Please find the presentation materials below.

Event Date: 
Sat, 06/18/2022 - 9:00am (EDT)
Conference Event Type: 

Catherine J. Lee, MD

Lee, Catherine
Associate Professor of Medicine in the Division of Hematology/BMT
Huntsman Cancer Center, University of Utah

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials.

Aplastic Anemia, MDS, and PNH Virtual Support Group - 2022 July

Event Date: 
Sat, 07/23/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

2022 San Antonio, TX, Patient and Family Virtual Conference

View each session from the San Antonio Patient and Family Virtual Conference with the links below:

Event Date: 
Sat, 03/26/2022 - 9:00am (EDT)
Conference Event Type: 

Aplastic Anemia, MDS, and PNH Virtual Support Group - 2022 June

Event Date: 
Sat, 06/25/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

BOSTON, May 25, 2022  – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with

Share with addtoany.com.